Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 ,inter alia, to consider and approve Un-Audited financials Results ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Drugs Ltd has informed BSE that its Board of Directors will meet on 14 February 2026 to consider and approve the un-audited standalone and consolidated financial results for the quarter ended 31 December 2025 (Q3 FY26). The filing is made as required under Regulation 29 of SEBI's Listing Obligations and Disclosure Requirements. The trading window for dealing in the company's shares has been closed for designated persons and their immediate relatives until 48 hours after the results are declared.
This is a standard regulatory intimation with no immediate impact on shareholders. Investors should watch the Q3 results announcement on or after 14 February 2026 for actual financial performance.